New York, NY and Paris, France (Press Release) – Cytovia Thera­peutics ("Cytovia"), an emerging bio­pharma­ceu­tical com­pany, an­nounces to­day that it has entered a re­search and licensing agree­ment with Inserm to de­vel­op NK engager bi-specific anti­bodies and iPSC CAR NK cell ther­apy targeting CD38, a key marker of mul­ti­ple myeloma. The licensing agree­ment has been negotiated and signed by Inserm Transfert, the private sub­sid­i­ary of Inserm, on behalf of Inserm (the French National In­sti­tute of Health and Medical Re­search) and its academic part­ners. Cytovia is licensing Inserm's CD38 anti­body and Chimeric Antigen Receptor (CAR) …

• Ongoing Phase 1/2a Study of CD19 CAR-NK with Pivotal Study Expected to Enroll Patients in 2021
• Potential to be the First CAR Cell Therapy Approved for Outpatient Admin­istra­tion

Houston, TX and Osaka, Japan (Press Release) – The University of Texas MD Anderson Cancer Center and Takeda Pharma­ceu­tical Com­pany Limited (TSE:4502/NYSE:TAK) (“Takeda”) to­day an­nounced an ex­clu­sive license agree­ment and re­search agree­ment to de­vel­op cord blood-derived chi­meric an­ti­gen re­cep­tor-directed natural killer (CAR NK)-cell ther­a­pies, ‘armored’ with IL-15, for the treat­ment of B-cell malig­nan­cies and other cancers.

Under the agree­ment, Takeda will re­ceive access to MD Anderson’s CAR NK plat­form and the ex­clu­sive rights to de­vel­op and com­mer­cial­ize up to four pro­grams, in­clud­ing a CD19-targeted …

• Collaboration Includes Exclusive Rights and Targets for Initial Appli­ca­tions in Non-Hodgkin Lymphoma, Leukemia and Multiple Myeloma
• Notch to Receive Upfront Payment, Research Funding and an Equity Investment Plus De­vel­op­ment and Commercial Milestones and Royalties on Net Sales

South San Francisco, CA and Toronto, ON (Press Release) – Allogene Thera­peutics, Inc. (Nasdaq: ALLO), a clin­i­cal-stage bio­technology com­pany pioneering the devel­op­ment of allo­geneic CAR T (AlloCAR T™) ther­a­pies for cancer, and Notch Thera­peutics Inc., an immune cell ther­apy com­pany creating universally compatible, allo­geneic T cell ther­a­pies for the treat­ment of dis­eases of high unmet need, to­day an­nounced an ex­clu­sive world­wide col­lab­o­ration and license agree­ment to re­search and de­vel­op induced pluripotent stem cell (iPSC) AlloCAR™ ther­apy prod­ucts for initial appli­ca­tion in non-Hodgkin lym­phoma, leukemia …

Initially Launching a Novel, High-Affinity BCMA CAR Targeting NK Cell De­vel­op­ment Candidate for Multiple Myeloma, with an Option for up to Five Additional CAR Targeting Sequences

San Diego, CA (Press Release) – NantKwest, Inc. (Nasdaq:NK), a leading clin­i­cal-stage Natural Killer (NK) cell based thera­peutics com­pany, and ProMab Biotech­nol­ogies to­day an­nounced the estab­lish­ment of a world­wide license to a B-Cell Maturation Antigen (BCMA) targeted anti­body sequence for mul­ti­ple myeloma along with an op­tion for up to five undisclosed targeting sequences for ex­clu­sive use in the devel­op­ment of chi­meric an­ti­gen re­cep­tor (CAR) based NK cell ther­a­pies.

“We are pleased to an­nounce this col­lab­o­ration with ProMab Biotech­nol­ogies, marking another mile­stone for NantKwest in the devel­op­ment of targeted, next gen­er­a­tion, NK cell thera­peutics …